$SRZN

Surrozen, Inc./DE (SRZN) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 2, 2026, Surrozen, Inc. (Surrozen) announced U.S. Food and Drug Administration (FDA) clearance of our Investigational New Drug (IND) application for SZN-8141, enabling us to advance the program into clinical development. The IND went into effect

Surrozen (SRZN) received FDA clearance for its IND application for SZN-8141, a treatment for diabetic macular edema. The company plans to begin dosing patients in Q4 2026. This milestone triggers a $95.1M second closing of a private placement. The funds will support the development of SZN-8141 and SZN-8143, as well as broader operating activities.

Guggenheim analyst Yatin Suneja named Surrozen Inc (SRZN) as the top biotechnology stock pick, citing progress in eye disease treatments. The company submitted an Investigational New Drug application for SZN-8141, triggering $98.4 million in funding. Guggenheim expects smooth IND clearance and clinical study initiations by late 2026. The analyst also noted upcoming Merck study results that could impact the sector.

Investing.com reports Guggenheim named Surrozen Inc. (SRZN) its top biotech stock pick, reiterating a Buy rating. The focus is the Phase IIb/III BRUNELLO readout, with primary completion expected in September and full data potentially in October. Guggenheim cites potential upside of 2 to 3 times current levels and highlights SRZN-8141/8143 and upcoming DUET timing.

Surrozen, Inc./DE (SRZN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026 Expect to initiate SZN-8141 Phase 1b/2a study, DUET, by year-end 2026 with initia

Investing.com reported Friday’s notable U.S. insider transactions. ClearSign (CLIR) director bought 500,000 shares for $1.77M at $3.54. Five Star Bancorp (FSBC) director bought 96,591 shares for $4.25M at $44. Rhinebeck Bancorp (RBKB) directors and CEO bought shares totaling about $596k. Levi (LEVI) CFO sold 98,144 shares for $2.38M. State Street (STT) sold 14,553 shares for $2.68M; Travelers (TRV) sold 6,000 for $2.2M; Domino’s (DPZ) sold about $4.0M.

TCG Crossover GP II, LLC sold 325,000 indirectly-held shares of Surrozen, Inc./DE (SRZN) at $21.25 ($6.91M total) across 2 trades on 2026-07-22.

Surrozen (NASDAQ:SRZN) presented preclinical data on SZN-8141, an antibody intended to activate Wnt signaling while inhibiting VEGF, and highlighted an IND filing planned for the second half of this year. Company speakers said combined Wnt agonism and VEGF inhibition improved efficacy in mouse models and may target retinal non-perfusion. The article also discussed SZN-8143 and IL-6’s role in retinal disease.

Surrozen to Present at Two Upcoming Healthcare Investor Conferences - Piper Sandler and ...

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule ...